Magazine
#16 Boehringer Ingelheim
Binger Strasse 173, 55216 Ingelheim, Germany
Tel: (49) 6132 77 0Fax: (49) 6132 77 3000
www.boehringer-ingelheim.com
| Headcount | 41,300 | |
| Year Established | 1817 | |
| Pharma Revenues | $13,405 | +13%/+6%* |
| Total Revenues | $17,060 | +14%/+6%* |
| Net Income | $2,101 | -15%/-21%* |
| R&D Budget | $3,103 | +19%/11%* |
* converted at avg. exch. rate / based on local currency (Euro)
| 2008 Top Selling Drugs | |||
| Drug | Indication | Sales | (+/-%) |
| Spiriva | COPD | $3,046 | +24% |
| Micardis | antihypertensive | $1,794 | +17% |
| Flomax | prostate | $1,582 | +13% |
| Sifrol/Mirapex | Parkinson's disease, restless legs | $1,106 | +25% |
| Combivent | respiratory | $814 | -8% |
Account for 62% of total pharma sales, up from 60% in 2006.
PROFILE
COPD treatment Spiriva continues to rake in cash for Boehringer-Ingelheim, passing the $3.0 billion mark in 2008. Two of its other three blockbusters — Flomax and Mirapex — go generic in 2010, so the company is already anticipating a drop in earnings in the next few years. Until that happens, it’ll market those two products as best it can. BI is also working on a new extended release version of Mirapex.
As with every other company in our ranks, BI is optimistic about its pipeline. In its annual report, the company touted its boost in R&D spending, at a time when other companies are touting their cuts. Chairman Andreas Barner remarked, “High R&D costs with disproportionately large increases are a good sign at Boehringer Ingelheim: [it means] our pipeline is well-filled, in particular with substances in late-stage clinical development.”
And BI isn’t just trying to follow-on its own products with new formulations. In June 2009, BI presented results from Phase II trials for linagliptin at the American Diabetes Association annual meeting. The company hopes to establish itself in the Type 2 diabetes market with the once-daily oral treatment, which has five Phase III trials in progress at present. Linagliptin (no trade name yet) is a DPP-IV inhibitor, which puts it in the same class as Merck’s Januvia, last seen doubling its sales in 2008 to $1.4 billion (and jumping 51% in 1Q09 to $411 million). That class also includes BMS/AZ’s Onglyza, and Novartis’ Galvus and a slew of others in development.
BI also plans to expand its Alzheimer’s program with a research collaboration. The company entered a pact with its diabetes partner Vitae Pharmaceuticals in June 2009, to explore beta-secretase (BACE) inhibitors for the treatment of Alzheimer’s disease. The initial deal was for as much as $250 million in upfront payments and pre-royalty milestones.
Later this summer, BI plans to present data from several large trials of Pradaxa, its oral anticoagulant that reached the European market in March 2008. Pradaxa is being tested against stroke prevention in atrial fibrillation, treatment of acute venous thromboembolic events (VTE), secondary prevention of VTE and prevention of cardiac events in patients with acute coronary syndrome (ACS).
BI is looking at some bumps in the road with Flomax and Mirapex’s expirations next year, but its replacements are going after some high-profile targets.
For the full Boehringer-Ingelheim profile, including pipeline and patent information, download the PDF.
Return to Top Pharma Report homepage.
